Peritoneal Integrity and Drug Response

Peritoneal dialysis (PD) is an effective method of renal replacement therapy (RRT) providing a high level of patient autonomy. During therapy, structural changes are however frequently occurring in the peritoneal membrane, which may lead to therapy failure after 3-5 years. Therefore, the aim of our group is to develop new therapeutic drugs delaying peritoneal deterioration and thereby improving peritoneal membrane function

Major Projects

Biobank “Peritonealdialyse) S569-PD, RBK
Peritoneal membrane integrity
Identification of deliverable drugs for treatment of PD patients in clinical practice
Establishment of a directional peritoneal model

Prof. Dr. Markus Ketteler

phone: ++49-711-8101 3496

Markus Ketteler

Selected References (2019-2022)

Schricker S, Oberacker T, Fritz P, Ketteler M, Alscher MD, Schanz M. Peritoneal Expression of SGLT-2, GLUT1, and GLUT3 in Peritoneal Dialysis Patients. Kidney & blood pressure research. 2022;47(2):125-34. Epub 2021/11/16.

Schanz M, Schöffski O, Kimmel M, Oberacker T, Göbel N, Franke UFW, et al. Under-recognition of Acute Kidney Injury after Cardiac Surgery in the ICU Impedes Early Detection and Prevention. Kidney & blood pressure research. 2022;47(1):50-60. Epub 2021/11/15.

Fusaro M, Tondolo F, Gasperoni L, Tripepi G, Plebani M, Zaninotto M, et al. The Role of Vitamin K in CKD-MBD. Current osteoporosis reports. 2022;20(1):65-77. Epub 2022/02/09.

Ketteler M, Wiecek A, Rosenkranz AR, Pasch A, Rekowski J, Hellmann B, et al. Efficacy and Safety of a Novel Nicotinamide Modified-Release Formulation in the Treatment of Refractory Hyperphosphatemia in Patients Receiving Hemodialysis-A Randomized Clinical Trial. Kidney international reports. 2021;6(3):594-604. Epub 2021/03/19.

Komaba H, Ketteler M, Cunningham J, Fukagawa M. Old and New Drugs for the Management of Bone Disorders in CKD. Calcified tissue international. 2021;108(4):486-95. Epub 2021/01/03.

Sánchez-Álvarez E, Rodríguez-García M, Locatelli F, Zoccali C, Martín-Malo A, Floege J, et al. Survival with low- and high-flux dialysis. Clinical kidney journal. 2021;14(8):1915-23. Epub 2021/08/05.

Rossignol P, Ruilope LM, Cupisti A, Ketteler M, Wheeler DC, Pignot M, et al. Recurrent hyperkalaemia management and use of renin-angiotensin-aldosterone system inhibitors: a European multi-national targeted chart review. Clinical kidney journal. 2020;13(4):714-9. Epub 2020/09/10.

Bellasi A, Raggi P, Bover J, Bushinsky DA, Chertow GM, Ketteler M, et al. Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification. Clinical kidney journal. 2021;14(1):366-74. Epub 2019/10/30.

Bushinsky DA, Raggi P, Bover J, Ketteler M, Bellasi A, Rodriguez M, et al. Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis: An Analysis of the Randomized, Placebo-Controlled CaLIPSO Study. Clinical journal of the American Society of Nephrology : CJASN. 2021;16(5):736-45. Epub 2021/04/10.

Fusaro M, Cianciolo G, Tripepi G, Plebani M, Aghi A, Politi C, et al. Oral Calcitriol Use, Vertebral Fractures, and Vitamin K in Hemodialysis Patients: A Cross-Sectional Study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2021;36(12):2361-70. Epub 2021/10/09.

Fusaro M, Cozzolino M, Plebani M, Iervasi G, Ketteler M, Gallieni M, et al. Sevelamer Use, Vitamin K Levels, Vascular Calcifications, and Vertebral Fractures in Hemodialysis Patients: Results from the VIKI Study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2021;36(3):500-9. Epub 2020/11/15.

Fusaro M, Tripepi G, Plebani M, Politi C, Aghi A, Taddei F, et al. The Vessels-Bone Axis: Iliac Artery Calcifications, Vertebral Fractures and Vitamin K from VIKI Study. Nutrients. 2021;13(10). Epub 2021/10/24.

Gosmanova EO, Chen K, Ketteler M, Rejnmark L, Mu F, Swallow E, et al. Risk of Cardiovascular Conditions in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study. Advances in therapy. 2021;38(8):4246-57. Epub 2021/06/25.

Hauser T, Dornberger V, Malzahn U, Grebe SJ, Liu D, Störk S, et al. The effect of spironolactone on diastolic function in haemodialysis patients. The international journal of cardiovascular imaging. 2021;37(6):1927-36. Epub 2021/02/06.

Ketteler M, Ambühl P. Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease. Journal of nephrology. 2021;34(5):1405-18. Epub 2021/06/26.

Ketteler M, Chen K, Gosmanova EO, Signorovitch J, Mu F, Young JA, et al. Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study. Advances in therapy. 2021;38(4):1946-57. Epub 2021/03/12.

Ketteler M, Schanz M, Schricker S. Vitamin K: should we supplement to protect the kidneys and the heart? Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2021;36(12):2196-8. Epub 2020/01/17.

Sprague SM, Ketteler M. A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert opinion on drug safety. 2021;20(12):1463-72. Epub 2021/09/14.

Weber T, Dotzenrath C, Dralle H, Niederle B, Riss P, Holzer K, et al. Management of primary and renal hyperparathyroidism: guidelines from the German Association of Endocrine Surgeons (CAEK). Langenbeck's archives of surgery. 2021;406(3):571-85. Epub 2021/04/22.

Chen KS, Gosmanova EO, Curhan GC, Ketteler M, Rubin M, Swallow E, et al. Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1-84). The Journal of clinical endocrinology and metabolism. 2020;105(10):e3557-65. Epub 2020/08/02.

Cozzolino M, Ketteler M, Wagner CA. An expert update on novel therapeutic targets for hyperphosphatemia in chronic kidney disease: preclinical and clinical innovations. Expert opinion on therapeutic targets. 2020;24(5):477-88. Epub 2020/03/20.

Raggi P, Bellasi A, Bushinsky D, Bover J, Rodriguez M, Ketteler M, et al. Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis: Results of a Randomized Phase 2b Study. Circulation. 2020;141(9):728-39. Epub 2019/11/12.

Raggi P, Bellasi A, Sinha S, Bover J, Rodriguez M, Ketteler M, et al. Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO Trial. Kidney international reports. 2020;5(12):2178-82. Epub 2020/12/12.

Cozzolino M, Ketteler M. Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD-MBD). Expert opinion on pharmacotherapy. 2019;20(17):2081-93. Epub 2019/11/02.

Ketteler M, Sprague SM, Covic AC, Rastogi A, Spinowitz B, Rakov V, et al. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2019;34(7):1163-70. Epub 2018/05/31.

Fernández-Martín JL, Dusso A, Martínez-Camblor P, Dionisi MP, Floege J, Ketteler M, et al. Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2019;34(4):673-81. Epub 2018/05/10.

Spitthöver R, Röseler T, Julius U, Heigl F, Schettler VJJ, Kühn R, et al. Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis. Journal of clinical apheresis. 2019;34(4):423-33. Epub 2019/03/01.

Verberne WR, Das-Gupta Z, Allegretti AS, Bart HAJ, van Biesen W, García-García G, et al. Development of an International Standard Set of Value-Based Outcome Measures for Patients With Chronic Kidney Disease: A Report of the International Consortium for Health Outcomes Measurement (ICHOM) CKD Working Group. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2019;73(3):372-84. Epub 2018/12/24.

Zoccali C, Blankestijn PJ, Bruchfeld A, Capasso G, Fliser D, Fouque D, et al. Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2019;34(7):1112-4. Epub 2019/03/01.

Curriculum Vitae Markus Ketteler, MD

Affiliation

Chief Physician
General Internal Medicine and Nephrology

Robert-Bosch-Hospital
Auerbachstr. 110
D-70376 Stuttgart
phone: ++49-711-8101 3496
fax: ++49-711-8101 3792
email: sekretariat-ketteler@rbk.de

Education and Professional Career

1989	M.D. degree, University of Heidelberg, Germany
1989 – 1992	Internship and Residency at the Department of Nephrology and Hypertension, University Hospital Steglitz, Free University Berlin, Germany
1992 – 1994	Post-Doctoral Fellowship (DFG) at the Division of Nephrology, University of Utah Health Sciences Center, Utah, USA
1994 – 2000	Residency/Clinical Fellowship at the Department of Endocrinology, Nephrology and Rheumatology, University Hospital Benjamin Franklin, Charité Berlin, Germany
2000 – 2007	Assistant Professor, Consultant (Nephrology/Internal Medicine) at the Department of Nephrology and Clinical Immunology, University Hospital Aachen, Germany
2007 – 2019	Division Chief of Nephrology, Klinikum Coburg, and Head of KfH-Nierenzentrum Coburg, Germany
2019 - present	Department Head of General Internal Medicine and Nephrology / Geriatrics at the Robert-Bosch-Krankenhaus Stuttgart, Germany

Professional Memberships

American Society of Nephrology (ASN)
International Society of Nephrology (ISN)
European Renal Association (ERA)
German Society of Nephrology (DGfN)
German Transplantation Society (DTG)
Council Member of the ERA 2009 – 2018, Congress President of the Annual ERA Congress 2021 in Berlin
Co-Chair of the KDIGO CKD-MBD Guideline Update 2015 – 2017
Board member of the Kidney Health Initiative (KHI) of the American Society of Nephrology (ASN) from 2017 – 2019
Board of Directors of the „Kuratorium für Dialyse und Nierentransplantation“ (KfH e.V.) 2020 – 2026
Executive Committee of the KDIGO Guideline Initiative 2020 - 2022

Scientific Journal Editorial Board Memberships

Nephrology, Dialysis & Transplantation (Theme Editor)
Clincal Nephrology
Journal of Nephrology